Regulation of VEGF by mevalonate pathway inhibition in breast cancer

Journal of Bone Oncology

Volumn 2, Issue 3, 2013, Pages 110-115

  Rachner, Tilman D ^a,d   Göbel, Andy ^a   Junker, Maria ^a   Hötzel, Josefa ^a   Benad Mehner, Peggy ^a   Hadji, Peyman ^b   Hofbauer, Lorenz C ^a,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atorvastatin; Breast cancer; Mevalonate pathway; Zoledronic acid

Indexed keywords

ATORVASTATIN; CALCIUM; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GGTI 298; HORMONE RECEPTOR; MEVALONIC ACID; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; RAP1 PROTEIN; RAP1A PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING;

EID: 84892791631     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2013.05.003     Document Type: Article

References (28)

1. Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 2007;16(Suppl. 3):S16-20.
2. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011;49:71-6.
3. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 1998;13:581-9. (Pubitemid 28163009)
4. Gnant M, Clézardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treatment Reviews 2012;38:407-15.
5. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine 2009;360:679-91.
6. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine 2011;365:1396-405.
7. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clinical Cancer Research 2007;13:4482-6. (Pubitemid 47219717)
8. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005;69:35-43. (Pubitemid 41207056)
9. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research 2002;62:6538-44. (Pubitemid 35364119)
10. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. American Journal of Pathology 2004;165:1865-74. (Pubitemid 39578366)
11. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. Journal of Bone and Mineral Research 2003;18:482-92. (Pubitemid 36241065)
12. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Medical Oncology 2008;25:346-9.
13. Benad P, Rauner M, Rachner TD, Hofbauer LC. The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. Cancer Letters 2011;312:101-8.
14. Metcalf S, Pandha HS, Morgan R. Antiangiogenic effects of zoledronate on cancer neovasculature. Future Oncology 2011;7:1325-33.
15. Bezzi M, Hasmim M, Bieler G, Dormond O, Rüegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. Journal of Biological Chemistry 2003;278:43603-14. (Pubitemid 37345986)
16. Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. European Journal of Cancer 2010;46:420-9.
17. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, et al. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Letters 2010;287:109-16.
18. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). Journal of Cellular and Molecular Medicine 2005;9:777-94. (Pubitemid 43116546)
19. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Research 1995;55:5687-92.
20. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. British Journal of Cancer 2001;85:273-8. (Pubitemid 32695751)
21. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Molecular Cancer Therapeutics 2009;8:2821-32.
22. Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Research 2010;70:10329-39.
23. Winter MC Wilson C Syddall SP, Cross SS, Evans A Ingram CE, et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer-a randomised biomarker pilot study. Clinical Cancer Research 2013;19:2755-65.
24. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11.
25. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2007;22:1479-91. (Pubitemid 351229318)
26. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nature Reviews Rheumatology 2011;8:90-6.
27. Yin G, Bai Y, Luo E. Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw. Medical Hypotheses 2011;76:347-9.
28. Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, et al. Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. Journal of Hematology & Oncology 2012;5:56.